UNSPSC 51171847: Pancopride

This classification denotes a serotonin antagonist with the molecular formula C18H24ClN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W80HW6Q65O, chemically known as benzamide, 4-amino-n-1-azabicyclo(2.2.2)oct-3-yl-5-chloro-2-(cyclopropylmethoxy)-, (+-)- but generally known as pancopride, which bears US NIH Compound Identifier 71342. European Medicines Agency schedules Pancopride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09602MIG.

UNSPSC 51171847 Pancopride is a Commodity code under which state and local governments procure drug testing services, specimen collection staffing, and associated laboratory and administrative infrastructure for offender monitoring and compliance programs. The recent solicitation activity shows demand for comprehensive specimen collection operations at multiple sites, immunoassay and confirmatory testing via LC/MS/MS or GC/MS, alternative testing methodologies including oral fluid and hair testing, and electronic result reporting integrated with randomized testing notification systems. Issuing bodies under this code include county criminal justice and community supervision departments managing offender caseloads; the code sees activity from regional and state-level entities managing substance abuse testing as a compliance and public safety function.

Collin County Community Supervision and Corrections Department in Texas posted RFP 2026-327 on July 9, 2026, seeking offender specimen collection and drug testing services with proposals due July 23, 2026. The scope encompasses staffing two collection sites in Plano and McKinney (Monday–Friday 8:00 a.m. to 5:00 p.m., plus five Saturdays annually 10:00 a.m. to 12:00 p.m.), operation of an Interactive Voice Response system for randomized testing notifications, immunoassay screening with LC/MS/MS or GC/MS confirmation, electronic result reporting, and oral fluid and hair testing options. Annual testing demand is approximately 25,031 tests comprising 5,452 five-panel screens and 18,006 six-panel screens with ancillary testing. The estimated contract value is $600,000 for a two-year initial term commencing September 1, 2026, with three optional one-year renewals. Pricing is per-test across three service models (screening only, confirmation after screening, and screening with automatic confirmation of positives), with vendor evaluation weighted 30 percent vendor understanding, 25 percent firm qualifications, 15 percent client references, and 30 percent cost, plus up to 30 points for optional Phase 2 demonstrations. Award is anticipated August 10, 2026. Successful vendors must maintain lab certification from SAMHSA, Texas Department of Public Safety, or CAP.